ReviewNature reviews. Disease primers2022
Juvenile idiopathic arthritis.
Review in Nature reviews. Disease primers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06870045 (Investigation of Validity and Reliability of Dynamic Walking Index in Childhood Rheumatic Diseases), which is not on this map. Cited by 175 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of Validity and Reliability of Dynamic Walking Index in Childhood Rheumatic Diseases
Who cites it
175 citing papers in PubMed, 5 syntheses or guidelines pooled it, 267 citations in OpenAlex.
- Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials.BMC medicine · 2024Pooled it
- Effect of exercise training on heath, quality of life, exercise capacity in juvenile idiopathic arthritis: a meta-analysis of randomized controlled trials.Pediatric rheumatology online journal · 2024Pooled it
- Early systemic inflammation induces neurodevelopmental disorders: results from ARTEMIS, a French multicenter study of juvenile rheumatisms and systemic autoimmune and auto-inflammatory disorders and meta-analysis.Molecular psychiatry · 2023Pooled it
- Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders.Advances in therapy · 2022Pooled it
- Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.Frontiers in immunology · 2022Pooled it
- The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with nicotinamide.Arthritis research & therapy · 2026Trial
- Predictors of inactive disease and remission in children and young adults with juvenile idiopathic arthritis treated with etanercept.Rheumatology (Oxford, England) · 2026Trial
- Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis.BMC pediatrics · 2025Trial
- A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Trajectories of Physical Function in Canadian Children With Juvenile Idiopathic Arthritis.Arthritis care & research · 2026Article
- Comorbidity and mortality in adults with juvenile idiopathic arthritis: a nationwide Norwegian register-based matched cohort study.Rheumatology (Oxford, England) · 2026Article
- Synovial Fluid Immune Cell Landscape in Juvenile Idiopathic Arthritis.European journal of immunology · 2026Article
- Digital home monitoring in patients with juvenile idiopathic arthritis to increase intervals of hospital visits.Rheumatology (Oxford, England) · 2026Article
- Identification and evaluation of 41 risk loci for juvenile idiopathic arthritis informs precision medicine: mechanistic implications of DNA topology and an HLA-A*02:01-ERAP2 interaction.medRxiv : the preprint server for health sciences · 2026Article
- The Long-Term Clinical and Radiographic Evolution of Temporomandibular Joint Involvement in Juvenile Idiopathic Arthritis: A Narrative Review and 15-Year Follow-Up Case Report.Children (Basel, Switzerland) · 2026Article
- The risk of neuropathy associated with biological therapy in juvenile idiopathic arthritis children.Clinical rheumatology · 2026Article
- Psychological Aspects of Rheumatic Diseases: Psychorheumatology in Clinical Practice.Rheumatology and therapy · 2026Review
- Article
- Hippocampal neuroinflammation and altered peripheral neurobiological protein profile in experimental arthritis and systemic juvenile idiopathic arthritis.EBioMedicine · 2026Article
- Single-cell profiling reveals CCL5Hi GZMAHi effector memory CD8 T cell association to oligoarticular JIA.Rheumatology (Oxford, England) · 2026Article
115 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
Abstract
Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age. JIA is the most common chronic inflammatory rheumatic condition of childhood. According to the International League Against Rheumatism (ILAR) classification, seven mutually exclusive categories of JIA exist based on disease manifestations during the first 6 months of disease. Although the ILAR classification has been useful to foster research, it has been criticized mainly as it does not distinguish those forms of chronic arthritis observed in adults and in children from those that may be unique to childhood. Hence, efforts to provide a new evidence-based classification are ongoing. Similar to arthritis observed in adults, pathogenesis involves autoimmune and autoinflammatory mechanisms. The field has witnessed a remarkable improvement in therapeutic possibilities of JIA owing to the availability of new potent drugs and the possibility to perform controlled trials with support from legislative interventions and large networks availability. The goal of drug therapy in JIA is to rapidly reduce disease activity to inactive disease or clinical remission, minimize drug side effects and achieve a quality of life comparable to that of healthy peers. As JIA can influence all aspects of a child's and their family's life, researchers increasingly recognize improvement of health-related quality of life as a key treatment goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.